Polyethylene Glycols - Therapeutic use
Research News and Information

Sunday, November 22, 2009

Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.

13 Oct 2009 BACKGROUND: The aim of this study was to assess the efficacy and safety of pegylated interferon (IFN) plus ribavirin (RBV) in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected patients with severe immunodeficiency in a ... Read more...

Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.

29 Sep 2009 The average age of patients initiating therapy for HCV is increasing, with older patients exhibiting lower responses to therapy than younger patients. Identification of those older patients likely to respond needs to be addressed. Using data from ... Read more...

Efficacy and safety of microfoam sclerotherapy in a patient with Klippel-Trenaunay syndrome and a patent foramen ovale.

29 Sep 2009 BACKGROUND: Sclerotherapy with polidocanol microfoam injection under duplex guidance is a new treatment for venous malformations associated with Klippel-Trenaunay syndrome. Multidetector-row computed tomography (MDCT) venography is extremely helpful ... Read more...

Latest indexed articles for 'Polyethylene Glycols - Therapeutic use'

These are the very latest articles for this heading:

• Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients. 30 Oct 2009
• Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. 13 Oct 2009
• Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. 29 Sep 2009
• Efficacy and safety of microfoam sclerotherapy in a patient with Klippel-Trenaunay syndrome and a patent foramen ovale. 29 Sep 2009
• Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. 29 Sep 2009
• Hepatitis C drug development at a crossroads. 29 Sep 2009
• Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. 29 Sep 2009
• Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. 29 Sep 2009
• [TNF-alpha blocking therapy in chronic inflammatory bowel disease] 18 Sep 2009
• Genomics: Hepatitis C virus gets personal. 15 Sep 2009
• Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment. 13 Sep 2009
• Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection. 13 Sep 2009
• An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant. 13 Sep 2009
• Baseline predictors of virological response for chronic hepatitis B patients. 12 Sep 2009
• IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. 11 Sep 2009
• Intravenous injections of soluble drag-reducing polymers reduce foreign body reaction to implants. 30 Aug 2009
• Hepatitis C: The role of new interferons in the era of STAT-C. 30 Aug 2009
• Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. 30 Aug 2009
• Association study of IFNAR2 and IL10RB genes with the susceptibility and interferon response in HBV infection. 30 Aug 2009
• Blue rubber bleb nevus syndrome successfully treated with polidocanol sclerotherapy and cryosurgery. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Polyethylene Glycols'

Definition: Polymers of ETHYLENE OXIDE and water and their ethers. They vary in consistency from liquid to solid, depending on the molecular weight, indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are lauromagrogols, nonoxynols, octoxynols and poloxamers.

Registry Number: 0

Descriptor UI: D011092

Alternative terms: Polyethylene Glycols; Glycols, Polyethylene; Polyethylene Glycol; Glycol, Polyethylene; Polyethylene Oxide; Oxide, Polyethylene; Polyethyleneoxide; Polyoxyethylenes; Macrogols; Carbowax-400; Carbowax 400; Carbowax400; PEG 1000; 1000, PEG; PEG 8000; 8000, PEG; Polyethylene Glycol 2000; 2000, Polyethylene Glycol; Glycol 2000, Polyethylene; Tritons; Vigilon; Polyethylene Glycol 400; 400, Polyethylene Glycol; Glycol 400, Polyethylene; PEO-400; PEO 400; Peg 400; PEG-400; Polyethylene Glycol 4000; 4000, Polyethylene Glycol; Glycol 4000, Polyethylene; Polyethylene Glycol 6000; 6000, Polyethylene Glycol; Glycol 6000, Polyethylene; PEG 6000; 6000, PEG; Polyox FRA; FRA, Polyox; Carbowax 600; 600, Carbowax; Polyethylene Glycol 300; 300, Polyethylene Glycol; Glycol 300, Polyethylene; Macrogol 300; 300, Macrogol;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; chemical synthesis; classification; diagnostic use; economics; history; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; chemistry; contraindications;

Pharmacological Action: Surface-Active Agents; Drug Carriers; Solvents;

Tree Number: D02.033.455.250.700; D05.750.741; D25.720.741; J01.637.051.720.741;

Online Note: to search TRITONS use POLYETHYLENE GLYCOLS 1975-82 & SURFACE-ACTIVE AGENTS 1966-74

History Note: 74; TRITONS was heading 1975-82, was see under AMMONIUM COMPOUNDS 1975-78, was see under SURFACE-ACTIVE AGENTS 1963-74